For questions concerning suggested order quantities or any other inquiries about MIRAPEX ER, please contact your Boehringer Ingelheim Pharmaceuticals, Inc. customer support specialist at 1-800-243-0127 or go to www.Bi-touchpoint.com.

Indication:
MIRAPEX ER tablets are indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease (PD).

Important Safety Information:
MIRAPEX ER may cause patients to fall asleep without warning signs during activities of daily living, including driving, which sometimes resulted in accidents. Some events may occur well after the start of treatment. Advise patients that, until they know how MIRAPEX ER affects them, or if they experience increased somnolence or episodes of falling asleep, they should not engage in potentially dangerous activities.

There have been reports of patients experiencing intense urges to gamble, increased sexual urges, intense urges to spend money, binge eating, and/or other intense urges, and the inability to control these urges while taking one or more of the medications that increase central dopaminergic tone and that are generally used for the treatment of PD, including MIRAPEX ER. Consider dose reduction or stopping MIRAPEX ER if a patient develops such urges.

As patients may not recognize or acknowledge increased drowsiness, sleepiness, or behavioral changes, prescribers should continually reassess patients.

Symptomatic orthostatic hypotension may occur, especially during initial treatment or dose escalation.

Hallucinations may occur at any time during treatment. MIRAPEX ER may potentiate the dopaminergic side effects of levodopa and may cause and/or exacerbate dyskinesia.

In a clinical trial for early PD, the most commonly reported adverse events with MIRAPEX ER that were more frequent than with placebo are somnolence, nausea, constipation, dizziness, fatigue, hallucinations, dry mouth, muscle spasms, and peripheral edema. In a clinical trial for advanced PD, the most commonly reported adverse events with MIRAPEX ER that were more frequent than with placebo are dyskinesia, nausea, constipation, hallucinations, headache, and anorexia.

Please click here to see full Prescribing Information.